hydrogen sulfide-releasing derivative of ketoprofen (ATB-352) / Antibe - LARVOL DELTA

MITOCHONDRIA-TARGETED DELIVERY OF HYDROGEN SULFIDE (H2S)-PRODRUG COUNTERACTS GASTROTOXICITY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. INVOLVEMENT OF HEME OXYGENASE PATHWAY (UEGW 2023) - "Importantly, new derivatives of NSAIDs, such as H2S-naproxen (ATB-346, Antibe Therapeutics Inc., Canada) or H2S-ketoprofen (ATB-352) exerted GI safety compared to mother compounds in preclinical or clinical studies. We showed that mitochondria-targeted H2S, released from very low i.g. doses of AP-39 improved gastric mucosal capacity to cope with NSAIDs-induced mitochondrial dysfunction and redox imbalance, mechanistically requiring the activity of anti-oxidative HMOX-1 and mitochondrial SOD-2. We assume that mitochondria-targeted H2S moieties could significantly increase the GI-safety of NSAIDs-pharmacology."

Gastrointestinal Disorder • Hematological Disorders • Inflammation • Metabolic Disorders • Mucositis • HMOX1 • IL10 • IL1B • SOD2 • STAT3 • TGFB1 • TNFA

Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results (Businesswire) - "Antibe Therapeutics Inc...has filed its financial and operating results for the fiscal quarter ended December 31, 2021....Launched preclinical studies for specialized pain indication for ATB-352"

Preclinical • Pain

[VIRTUAL] IMPACT OF NOVEL HYDROGEN SULFIDE-RELEASING KETOPROFEN (ATB-352) ON MOLECULAR PATHWAYS AND MICROBIOME PROFILE IN GASTROINTESTINAL (GI) TRACT WITH POSSIBLE DEVELOPMENT OF GI-SAFE POLYPHARMACY WITH OTHER NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) (DDW 2021) - "H2S-releasing NSAIDs derivatives seem to be promising safer and more effective alternatives; H2S-naproxen (ATB-346) successfully finished phase II clinical trial...Omeprazole decreased ketoprofen-induced injury score to the level of ATB-352 applied alone... ATB-352 applied alone or in polypharmacy with aspirin effectively inhibits COX activity, is GI-safe due to its H2S-releasing ability and has lower impact on molecular oxidative- or inflammatory-response pathways and intestinal microbiome composition as compared with its parent drug. We conclude that GI-safety of H2S-releasing ketoprofen does not require polypharmacy with PPIs and involves maintenance of intestinal microbiota profile and HMOX-1, CREB and SOCS3 pathways activation. ["

Gastrointestinal Disorder • Inflammation • HMOX1

Future prospects of ketoprofen in improving the safety of the gastric mucosa. (PubMed, Biomed Pharmacother) - "Our review confirms that modifications of K maintain its' desirable actions and decrease ulcer producing side effect. Some new forms of K were also found to have better activity profile compared to the parent drug."

Clinical • Journal • Review • Pain

Microbiome profile and molecular pathways alterations in gastrointestinal tract by hydrogen sulfide-releasing non-steroidal anti-inflammatory drug (ATB-352). Insight into possible safer polypharmacy. (PubMed, Antioxid Redox Signal) - "Neither compound affected DNA oxidation in the GI mucosa but ATB-352 had lower impact on molecular oxidative-/inflammatory-response pathways and intestinal microbiome. The GI safety of ATB-352 could be due to the involvement of heme oxygenase-1 and SOCS3 pathways activation."

Journal • Gastrointestinal Disorder • Inflammation • HMOX1 • mTOR

Antibe Therapeutics Provides 2021 Corporate Update (Businesswire) - "...we commissioned a market opportunity assessment to guide the detailed development of our second drug, ATB-352, an opioid replacement aimed at the post-operative pain market. The study provided important input for trial design and confirmed the large unmet medical need for a gastrointestinal-safe NSAID for acute pain, projecting peak year sales exceeding US$800 million in the U.S. alone."

Sales projection • Pain

Effect of Ketoprofen and ATB-352 on the Immature Human Intestine: Identification of Responders and Non-responders. (PubMed, J Pediatr Gastroenterol Nutr) - "These results show less damaging effects of ketoprofen compared to indomethacin on the immature intestine and indicate that the intestinal response to this NSAID significantly varies between individuals. However, the results did not allow us to demonstrate a specific beneficial effect of H2S release in organ culture."

Journal • Gastrointestinal Disorder

Antibe Therapeutics engages Stern IR to expand its investor relations program and broaden visibility within US capital markets (Proactiveinvestors) - "Antibe Therapeutics Inc....said it has engaged Stern Investor Relations, Inc. to expand the company’s investor relations program and support efforts to broaden visibility within the US capital markets."

Licensing / partnership • Osteoarthritis • Pain

Antibe Therapeutics Provides Corporate Update (Businesswire) - "ATB-352 Advancing Towards Clinical Development Next Year:...We have commenced IND-enabling preclinical studies for our second pipeline drug, ATB-352....We anticipate that preclinical studies of ATB-352 will conclude in calendar Q3 2021, following which we will seek regulatory approval to initiate human trials. We plan to pursue a Fast Track designation with the FDA to expedite the development and regulatory approval process."

IND • Preclinical • Pain

Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering (Yahoo Finance) - "Antibe Therapeutics Inc....announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the 'Units') at a price of $0.40 per Unit (the 'Offering Price') plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the 'Offering')...The Company intends to use the net proceeds of the Offering to fund certain activities required to support large market partnering and begin the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company's pipeline including ATB-352."

Financing • CNS Disorders • Osteoarthritis • Pain

Antibe Therapeutics announces $25 million bought deal unit offering (Businesswire) - "Antibe Therapeutics Inc....today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc....The net proceeds of the Offering will be used to fund activities required for large market partnering and in support of the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company’s pipeline including ATB-352."

Financing • Osteoarthritis • Pain